Paper6430643
Phenoxybenzamine--an effective male contraceptive pill.
Homonnai ZT and 2 others. Contraception, 1984. Cited by 30 papers, by iCite.
Cite this record
ConductScience Library. Phenoxybenzamine--an effective male contraceptive pill. Papers, record 6430643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6430643
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Contraceptive Agents, Male | Major topic |
| Phenoxybenzamine | Major topic |
| Adult | |
| Blood Pressure | |
| Dose-Response Relationship, Drug | |
| Ejaculation | |
| Follicle Stimulating Hormone | |
| Humans | |
| Luteinizing Hormone | |
| Male | |
| Middle Aged | |
| Prolactin | |
| Semen | |
| Sperm Count | |
| Testosterone |
Source PubMed
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41269482 | Efficacy of daily silodosin 8 mg as a potential reversible male contraceptive: A prospective placebo controlled study. | Int Urol Nephrol | 2026 | https://conductscience.org/library/papers/41269482 | PubMed |
| 38716676 | Emerging approaches to male contraception. | Andrology | 2024 | https://conductscience.org/library/papers/38716676 | PubMed |
| 36909934 | Emerging concepts in male contraception: a narrative review of novel, hormonal and non-hormonal options. | Ther Adv Reprod Health | 2023 | https://conductscience.org/library/papers/36909934 | PubMed |
| 36008555 | Current and emerging treatment options for premature ejaculation. | Nat Rev Urol | 2022 | https://conductscience.org/library/papers/36008555 | PubMed |
| 34697263 | Roles for α1-adrenoceptors during contractions by electrical field stimulation in mouse vas deferens. | Korean J Physiol Pharmacol | 2021 | https://conductscience.org/library/papers/34697263 | PubMed |
| 31076850 | A prospective double-blind, randomized, placebo-controlled study to evaluate the efficacy of silodosin 8 mg as an on-demand, reversible, nonhormonal oral contraceptive for males: a pilot study. | World J Urol | 2020 | https://conductscience.org/library/papers/31076850 | PubMed |
| 29928620 | The future of male contraception: a fertile ground. | Transl Androl Urol | 2018 | https://conductscience.org/library/papers/29928620 | PubMed |
| 28868816 | Hypertension and Male Fertility. | World J Mens Health | 2017 | https://conductscience.org/library/papers/28868816 | PubMed |
| 24297884 | Male contraception via simultaneous knockout of α1A-adrenoceptors and P2X1-purinoceptors in mice. | Proc Natl Acad Sci U S A | 2013 | https://conductscience.org/library/papers/24297884 | PubMed |
| 22870014 | Antifertility activity of Cryptolepis sanguinolenta leaf ethanolic extract in male rats. | J Hum Reprod Sci | 2012 | https://conductscience.org/library/papers/22870014 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6430643
GET https://conductscience.org/api/papers/v1/6430643/authors